<?xml version='1.0' encoding='utf-8'?>
<document id="20199976"><sentence text="Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer."><entity charOffset="52-62" id="DDI-PubMed.20199976.s1.e0" text="vinflunine" /><entity charOffset="83-92" id="DDI-PubMed.20199976.s1.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.20199976.s1.e0" e2="DDI-PubMed.20199976.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s1.e0" e2="DDI-PubMed.20199976.s1.e1" /></sentence><sentence text="A multicenter phase I/II trial of vinflunine administered in combination with cisplatin at 80 mg/m(2) was conducted in order to determine the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose of the combination"><entity charOffset="34-44" id="DDI-PubMed.20199976.s2.e0" text="vinflunine" /><entity charOffset="78-87" id="DDI-PubMed.20199976.s2.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.20199976.s2.e0" e2="DDI-PubMed.20199976.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s2.e0" e2="DDI-PubMed.20199976.s2.e1" /></sentence><sentence text=" An eventual mutual pharmacokinetic drug-drug interaction when vinflunine and cisplatin were coadministered was also evaluated"><entity charOffset="63-73" id="DDI-PubMed.20199976.s3.e0" text="vinflunine" /><entity charOffset="78-87" id="DDI-PubMed.20199976.s3.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.20199976.s3.e0" e2="DDI-PubMed.20199976.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s3.e0" e2="DDI-PubMed.20199976.s3.e1" /></sentence><sentence text=" The study was also intended to define the response rate of vinflunine in combination with cisplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) at the recommended dose"><entity charOffset="60-70" id="DDI-PubMed.20199976.s4.e0" text="vinflunine" /><entity charOffset="91-100" id="DDI-PubMed.20199976.s4.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.20199976.s4.e0" e2="DDI-PubMed.20199976.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s4.e0" e2="DDI-PubMed.20199976.s4.e1" /></sentence><sentence text="" /><sentence text="Patients were required to have a histologically confirmed diagnosis of NSCLC not amenable to curable treatment or stage IV disease" /><sentence text=" Patients may have had previous surgery for NSCLC but were to be chemonaive and have at least 1 bidimensional measurable lesion outside an irradiated area" /><sentence text="" /><sentence text="The recommended dose was established at cisplatin 80 mg/m2 combined with vinflunine 320 mg/m(2)"><entity charOffset="40-49" id="DDI-PubMed.20199976.s9.e0" text="cisplatin" /><entity charOffset="73-83" id="DDI-PubMed.20199976.s9.e1" text="vinflunine" /><pair ddi="false" e1="DDI-PubMed.20199976.s9.e0" e2="DDI-PubMed.20199976.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s9.e0" e2="DDI-PubMed.20199976.s9.e1" /></sentence><sentence text=" No unexpected adverse events were seen" /><sentence text=" Pharmacokinetic analysis supported the absence of mutual pharmacokinetic interaction when vinflunine and cisplatin are given in combination"><entity charOffset="91-101" id="DDI-PubMed.20199976.s11.e0" text="vinflunine" /><entity charOffset="106-115" id="DDI-PubMed.20199976.s11.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.20199976.s11.e0" e2="DDI-PubMed.20199976.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s11.e0" e2="DDI-PubMed.20199976.s11.e1" /></sentence><sentence text=" Treatment of 53 patients at this recommended dose demonstrated a tumor response rate of 32" /><sentence text="1% in the intent-to-treat population; disease control was achieved in 79" /><sentence text="2% of the patients" /><sentence text=" The median progression-free survival and overall survival were estimated at 5 months and 10" /><sentence text="4 months, respectively, and the 1-year survival rate was 43" /><sentence text="4%" /><sentence text="" /><sentence text="These results place the vinflunine/cisplatin combination among the most active doublets in this treatment setting and warrant further development in phase III trials of first-line treatment of patients with advanced metastatic NSCLC"><entity charOffset="24-34" id="DDI-PubMed.20199976.s19.e0" text="vinflunine" /><entity charOffset="35-44" id="DDI-PubMed.20199976.s19.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.20199976.s19.e0" e2="DDI-PubMed.20199976.s19.e0" /><pair ddi="false" e1="DDI-PubMed.20199976.s19.e0" e2="DDI-PubMed.20199976.s19.e1" /></sentence><sentence text="" /></document>